Steroid-refractory Autoimmune Hemolytic Anemia Following Unrelated Allogeneic Peripheral Blood Stem Cell Transplantation
| Autor: | Yeo-Kyeoung Kim, Soo-Young Bae, Sang-Hee Cho, Ik-Joo Chung, J. Yoon, Je-Jung Lee, Deok-Hwan Yang, Jae-Sook Ahn, Seong-Rye Seo, Seong-Wook Lim, Hyeoung-Joon Kim |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cyclophosphamide business.industry medicine.medical_treatment Splenectomy General Engineering Hematopoietic stem cell transplantation medicine.disease Gastroenterology Imatinib mesylate hemic and lymphatic diseases Internal medicine ABO blood group system medicine Rituximab Autoimmune hemolytic anemia business medicine.drug Chronic myelogenous leukemia |
| Zdroj: | Chonnam Medical Journal. 44:184 |
| ISSN: | 0377-9564 |
| DOI: | 10.4068/cmj.2008.44.3.184 |
| Popis: | A 29 years old female with chronic myelogenous leukemia underwent an unmanipulated, unrelated, HLAmatched peripheral blood stem cell transplantation (PBSCT) after imatinib mesylate treatment. The patient and donor had different ABO blood types and at 1 year later after PBSCT, the patient showed severe autoimmune hemolytic anemia (AIHA). She was treated with several immunosuppressive agents including high-dose steroid, cyclophosphamide, intravenous immunoglobulin and rituximab and underwent multiple sessions of plasma exchange. As her AIHA showed no response to these multiple therapies, she underwent splenic artery embolization and splenectomy. After then her AIHA was resolved with low dose oral steroid maintenance. Although the incidence of AIHA is known to be increased after allogeneic hematopoietic stem cell transplantation (HSCT), it has been rarely reported in Korea. Since AIHA in the setting of post-allogeneic HSCT is often difficult to treat and the prognosis is very poor, the accurate and early diagnosis is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|